Canada: Case Summary For Pfizer v Canada (2014 FC 1243, 2016 FCA 248)

Last Updated: July 5 2017
Article by Adam Bobker and Shuo Xing

The Federal Court of Appeal decision in Pfizer v. Canada (2016 FCA 248) upheld the Minister of Health's interpretation that the 24-month stay for patent owners provided for in the PM (NOC) regulations was not available when two (2) companies sought permission (an NOC) to market generic drugs that had already been shown to be as safe and effective as patented drugs. On June 22, 2017, the Supreme Court of Canada denied leave to appeal. Going forward, it is going to be more difficult to seek judicial review of decisions of the Minister of Health under the PM (NOC) regulations if the regulations reasonably support the decision. The Court is not likely to substitute its interpretation unless the Minister's interpretation is seen as unreasonable.

In its 2016 FCA 248 decision the Federal Court of Appeal had reversed an earlier Federal Court decision and held that reasonableness is the correct standard of review to be applied to decisions of the Minister of Health in the context of the PM (NOC) regulations. Applying the reasonableness standard, the FCA upheld the Minister's interpretation of the PM (NOC) Regulations that s. 5 of the Regulations that require patents to be addressed and, thereby, allow for a 24 month stay if prohibition proceedings are taken should not be engaged when a drug submission for notice of compliance (NOC) is purely administrative (eg. name change).

The decision relates to two separate judicial reviews before the Federal Court, both brought by innovator pharmaceutical companies of the Minister's decision to grant NOC's to generic companies for drugs containing active ingredients patented by the innovator companies. On the one hand, Pfizer Inc (Pfizer) sought judicial review over the Minister's decision to grant a NOC to Teva Pharmaceuticals (Teva) for a drug containing the active ingredient exemestane, a breast cancer drug sold and patented by Pfizer in Canada. Initially, a New Drug Submission (NDS) for exemestane was submitted by Generic Medical Partners Inc (GMP) in which GMP referenced Pfizer's patented product and accordingly sent the innovator a Notice of Allegation (NOA) challenging its patent. Pfizer chose not to respond to the NOA since GMP did not sell any product in Canada; thus a NOC was granted to GMP. Teva through a licensing agreement with GMP became the Canadian distributor of the new exemestane product and filed a NDS seeking to change the brand name and the marketer without altering the content of the drug product. A NOC was granted to Teva. In a separate case, Celltrion Healthcare Co Ltd (Celltrion) applied for and obtained a NOC to market its subsequent entry biologic Inflectra, which referenced Janssen Inc (Janssen)'s product infliximab. Because Janssen had not yet received a patent at the time of Celltrion's NDS, no NOA was sent and Celltrion did not address any patent issues. After Janssen's patent covering infliximab was granted, Hopsira filed a NDS and obtained a NOC in the capacity of the Canadian distributor of inflectra as named by Celltrion in its earlier NDS.

In both instances, the Minister's decision to issue NOC to the licensee generic company without requiring the generic company to address the innovator's patent was under review. In analyzing Pfizer's case, after an extensive review of case law pre- and post-Dunsmuir2, the Federal Court established the process to determine the appropriate standard of review. First, one must consider whether the standard of review for the particular issue has been satisfactorily settled in case law. Second, if it has not been settled, the following categories of issues attract a standard of correctness: (1) a constitutional question, (2) a question of general legal importance that is outside of the expertise of the decision-making body, (3) a determination of respective jurisdiction of two decision-making bodies, and (4) a true jurisdictional question. Conversely, if the issue involves a factual or a mixed fact and law determination or if it involves the exercise of a statutorily-conferred discretion or making a policy-based decision that the decision-maker is mandated to make, the standard should be reasonableness. Finally, the Federal court recognized that there is a presumption that the reasonableness standard applies whenever an administrative decision-maker interprets its constituent statute or a statute closely related to its function. However, the Federal Court notes that this presumption can still be rebutted through a contextual analysis using the relevant factors set out in Dunsmuir: existence of a privative clause, nature of the tribunal, nature of question at issue, and expertise of the tribunal2.

Applying this framework to the Pfizer case, the Federal Court had concluded that the appropriate standard of review should be correctness since although the presumption of reasonableness exists in the case of Minister of Health interpreting PM(NOC) Regulations, there is no privative clause in the Regulations, the wording of the Regulations did not afford the Minister any discretion on whether to issue a NOC and the ultimate power whether a NOC should issue resides with the Court. On the standard of correctness, the Federal Court found the Minister's decision to be incorrect since allowing generic companies to not address relevant patents listed against their submissions, the Minister failed to achieve proper balance between the rights of innovators, generic companies and the public, a key purpose of the PMNOC Regulations.

While agreeing with the framework set out by the Federal Court in general, the Federal Court of Appeal arrived at a different conclusion and found that the presumption of reasonableness was not rebutted. According to the Federal Court of Appeal, the fact that PM(NOC) Regulations do not suggest deference does not point away from the reasonableness standard; the proper inquiry following the Supreme Court decision in Tervita should be whether the Regulations evidence Parliament's intent that the decisions of the Minister interpreting the Regulation should be reviewed on a less deferential standard3. Unable to identify any indication to this effect in the PM(NOC) Regulations, the court of appeal concluded that the Minister's interpretations should attract the standard of reasonableness, especially since the statute is very closely related to the Minister's function.

In determining whether the Minister's interpretation was reasonable, the Federal Court of Appeal looked to the Supreme Court decision in Biolyse, in which the Supreme Court interpreted the term "submission" in the then current version of s.5(1.1) of the Regulations by looking to "reciprocal provision" s.4(1) of the Regulations4. In Biolyse, the SCC concluded that submissions should be considered on an individual basis in order to determine whether it is a submission that triggers s. 4 or 5 of the PM(NOC) Regulations. Turning to Hoffmann-La Roche, the court of appeal noted that a NDS should be assessed by asking whether the changes reflected within give rise to a new or different basis for asserting that a particular product is infringing5. Thus, the Minister acted reasonably in deciding that the submissions were purely administrative in nature, did not submit any new data, and did not trigger s.5 procedures.

Footnotes

1 Dunsmuir v New Brunswick, 2008 SCC 9.

2 Ibid.

3 Tervita Corp v Canada (Commissioner of Competition), 2015 SCC 3.

4 Bristol-Myers Squibb Co v Canada (AG), 2005 SCC 26.

5 Hoffmann-La Roche Ltd v Canada (Minister of Health), 2006 FCA 335.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Adam Bobker
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.